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Abstract: Background: Up to half of the patients with schizophrenia attempt suicide during their
lifetime. Better insight is associated with better functioning but also with increased suicidality.
The direction of the relationship between insight and suicidality is not clear, hence we aimed
J. Clin. Med. 2019, 8, 1196; doi:10.3390/jcm8081196 www.mdpi.com/journal/jcm
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to provide new elements using structural equation modeling. Methods: Insight, quality of life
(QoL), depression, and suicidality were measured at baseline and at 12 months in individuals with
schizophrenia spectrum disorders. The relationships between these variables were investigated by
latent difference score models, controlling for chlorpromazine doses, positive and negative symptoms,
and general psychopathology. Results: 738 patients were included, and 370 completed the study.
Baseline levels of insight predicted changes in suicidality, whereas baseline levels of suicidality did
not predict changes in insight, suggesting that better insight underlies suicidality and predicts its
worsening. Our results suggest this temporal sequence: better insight→ worse QoL→ increased
depression→ increased suicidality, while insight also affects the three variables in parallel. Conclusion:
Better insight predicts a worsening of QoL, depression and suicidality. These findings contribute to
our global understanding of the longitudinal influence of insight on suicidality. We advocate that
insight-targeted interventions should not be proposed without the monitoring of depression and
suicide prevention.
Keywords: Schizophrenia; suicide; insight; quality of life; depression; structural equation modeling
1. Introduction
Schizophrenia is a severe and persistent psychiatric disorder, characterized by heterogeneous
symptomatology and cognitive impairments. Objective measures of functioning and subjectively
reported quality of life (QoL) are negatively affected in schizophrenia and most patients are unemployed,
unable to maintain social relationships or to live independently [1]. Schizophrenia is associated with a
12-fold increased relative risk of suicide and a lifetime risk of 5 to 6.5% [2,3]. Up to 50% of patients
with schizophrenia attempt suicide in their lifetime [4], making it a major issue for this population.
Between 50 and 75% of the patients with schizophrenia have poor insight [5,6], i.e., difficulties
in describing their mental condition and its social consequences, attributing their symptoms to their
disease and acknowledging the necessity of seeking treatment [5]. Poor insight is associated with worse
clinical outcomes [6]. It is, thus, common practice to try and improve patients’ insight [7]. However,
improving insight may not have only positive effects. This situation is called the “insight paradox”.
It has been shown that better insight may be associated with increased depression and poorer QoL
in schizophrenia [8–11]. Although research addressing this question has yielded inconsistent results,
mostly because of methodological discrepancies, a recent meta-analysis [12] has provided evidence
supporting the existence of a longitudinal relationship between higher insight and increased depression.
Higher insight also appears to be associated with suicidality (suicide attempts and ideation) [13–15].
Massons et al. (2017) suggested that depression may mediate the relationship between insight and
suicidality [16], and others have shown an association between higher suicidality and poorer QoL [17].
By adopting an integrative perspective, Roux et al. [18] proposed a refinement of this model in a
cross-sectional study of the relationships between insight, depression, QoL and suicidality using
mediation analyses with structural equation modeling (SEM). They found an indirect link between
insight and suicidality, fully mediated by poor QoL and increased depression; higher insight was
associated with increased depression, directly, and indirectly through QoL, and depression fully
mediated the relationship between QoL and suicidality (see Figure S1).
The putative causal mechanism suggested here remains fragile, however, given the divergent
results from longitudinal studies. First of all, a history of suicide attempt before the first episode of
schizophrenia has been associated with better insight at the time of the first psychotic episode [15],
whereas insight at that time was not associated with later suicide attempts beyond the association
with depression [19], suggesting that suicide attempters may be more likely to acknowledge their
mental illness. Furthermore, one study interestingly reported that baseline clinical insight predicted
higher suicidality during a two-year period, whereas insight improvement during the follow-up was
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associated with lower suicidality [20]. This apparent contradiction highlights the possibility that
longitudinal models may lead to different results, depending on whether they focus on absolute values
or changes over time, and underscores the need for further investigation using robust longitudinal
statistical methods such as SEM. Lastly, two potential causal directions have been reported concerning
the relationships between QoL and depression: a study found that depression predicted further
QoL [21], another one found that that QoL predicted further depression [22]. Here, again, the need
to simultaneously test the possible directions of this relationship within the same model would help
in determining the causal predominance. Latent difference score (LDS) analysis [23] provides a way
to address the issue of longitudinal causal ordering between variables. It is a robust method for
investigating whether the value of a variable predicts further changes in other variables.
We aimed to study the direction of the relationships between insight, QoL, depression,
and suicidality in patients with schizophrenia spectrum disorders using longitudinal SEM. The main
hypothesis was that better insight at inclusion predicts a worsening of suicidality, but not the reverse.
We also hypothesized that better insight predicts a deterioration in QoL, that worse QoL predicts
a worsening of depression, and that worse depression predicts an increase in suicidality, but not
the reverse.
2. Experimental Section
2.1. Study Design
This multi-center longitudinal study included patients recruited into the FondaMental Academic
Centers of Expertise for Schizophrenia (FACE-SZ) cohort between March 2010 and June 2017 by a French
nationwide network of 10 schizophrenia expert centers (Bordeaux, Clermont-Ferrand, Colombes,
Créteil, Grenoble, Lyon, Marseille, Montpellier, Strasbourg, and Versailles). This network was set up by
the FondaMental Foundation (www.fondation-fondamental.org) and funded by the French Ministries
of Research and Health to build links between systematic clinical assessment and research.
2.2. Participants
Schizophrenia, schizoaffective disorder, or schizophreniform disorders were diagnosed based on
the Structured Clinical Interview for assessing DSM-IV-R criteria. Patients were interviewed by senior
psychiatrists or psychologists specialized in schizophrenia, who were all members of the specialized
multidisciplinary teams of the expert centers. We included only clinically stable patients (no admission
or treatment change in the past four weeks), between 15 and 65 years of age.
The assessment protocol was conducted in accordance with the Declaration of Helsinki and was
approved by the ethics review board (CPP-Ile de France IX, 18 January 2010), which required that all
patients be provided with an informational letter but waived the requirement for written informed
consent. However, we sought the verbal agreement of every patient before inclusion.
2.3. Measures
Patients were evaluated at inclusion, and one year later.
Insight was assessed using both self-report (Birchwood Insight Scale, BIS [24,25]) and clinician-rated
(Scale to assess Unawareness of Mental Disorder, SUMD [26,27]) scales, as recommended [28]. Higher
BIS scores and lower SUMD scores indicate better insight. We used the mean of the first three items
of the SUMD, which are general items concerning the disease (consciousness of the disease, of its
consequences and of the necessity to seek treatment). The item “lack of judgement and insight” (G12)
of the general psychopathology part of the Positive and Negative Syndrome Scale (PANSS) was used
as a third measure of insight.
QoL was assessed using the Schizophrenia Quality of Life Questionnaire (S-QoL 18) [29],
a self-report scale, explained by an eight-factor structure: psychological well-being, physical well-being,
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self-esteem, family relationships, relationships with friends, resilience, autonomy, and sentimental life.
Higher scores indicate better QoL.
Depressive symptoms were evaluated with the Calgary Depression Rating Scale (CDS) for
Schizophrenia, a structured interview scale. Higher scores indicate worse depression [30,31]. We
subtracted the item “suicide” from the CDS score to avoid overlap between variables, as we used
another measure for suicidality, described below.
The risk of suicide was assessed during a clinician interview that explored the patient’s experience
during the past 12 months. A six-level ordinal scale ranging from 0 to 5 was used: 0, no death thoughts,
suicidal ideation, or suicidal behavior; 1, patient believes life is not worth living; 2, patient has death
wishes; 3, patient has already thought about committing suicide, but knowing she/he would never act;
4, patient has seriously thought about, or made plans for, committing suicide; 5, patient has attempted
suicide. The scoring procedure was derived from the Columbia Suicide Severity Rating Scale [32],
which proposes to report the most severe suicidal ideation category rated on a 5-point ordinal scale
The severity of schizophrenic symptoms was assessed using the Positive and Negative Syndrome
Scale (PANSS) [33]. The positive symptoms, negative symptoms and general psychopathology scores
were used. We subtracted the item G12 from the general psychopathology score, as this item was used
as a measure of insight.
2.4. Analyses
We calculated Pearson’s zero-order correlations between the variables of interest. We analyzed
the evolution of the variables between inclusion and follow-up using Student’s t tests for continuous
variables (and additional Wilcoxon’s signed ranks test when non-normality was found in a variable)
and Chi2 tests for categorical variables. Effect sizes were estimated using Cohen’s d with 0.2, 0.5,
and 0.8 as lower bounds for small, moderate and high effect size [34].
We compared scores at inclusion between individuals who dropped-out during the follow-up
(non-completers) and those who completed both evaluations (completers) to check for potential
attrition bias.
2.4.1. Models
We performed structural equation modeling (SEM) using the lavaan [35] package in R. Missing
data were handled with full information maximum likelihood [36]. We used LDS modeling to analyze
the data [23] with a robust maximum likelihood estimator with Satorra–Bentler adjustment to account
for non-normality in variables [37]. LDS models allow for testing the effect of a variable on subsequent
change in another variable (∆) to infer a direction in the association between two variables. This method
is a powerful means to estimate bivariate and multivariate coupling [38].
We estimated the required sample size to 286 patients (see Supplementary Methods). Consensual
fit indices were inspected [39–41]: the comparative fit index (CFI) and Tucker–Lewis index (TLI) should
be > 0.9, the root mean square error of approximation (RMSEA), reported with the p-close, which
should be > 0.05 and the standardized root mean residual (SRMR) should be < 0.08 to assume a good fit.
2.4.2. Latent Variables and Longitudinal Invariance
Insight was defined as a latent variable with three indicators: BIS total score, mean of the three
general items of the SUMD, and PANSS item G12. QoL was defined as a latent construct with eight
indicators, corresponding to the dimensions assessed by the S-QoL 18. We checked for longitudinal
invariance of the latent constructs (see Supplementary Methods).
2.5. Procedure
We successively tested several models to disentangle the relationships between insight, QoL,
depression, and suicidality in schizophrenia spectrum disorder. Figure 1 presents the specification of a
LDS model with one latent variable X and one observed variable Y [38]; this example represents the
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“reciprocal” model described below. In this method, the unstandardized path coefficient from the XT0
and XT12 is fixed to 1, as is the factor loading of XT12 on the latent variable, representing the change in X.
Paths of interest are β (autoregressive path: association between a variable’s initial value and its own
change) and γ (coupling path: association between a variable’s initial value and the other variable’s
change). Significant coupling paths are generally interpreted as causal paths from one variable to
another. Covariance between latent changes and between variables at T0 was estimated. Indicators in
latent variables at T0 were allowed to correlate with themselves at T12.
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We first estimated six bivariate models obtained by combining the four variables of interest,
two-by-two, and successively compared different models to test the nature and direction of
putative relationships:
• Autoregressive model: only autoregressive paths (β)
• Expected model: autoregressive model + path XT0→ ∆Y (β + γ1)
• Reverse model: autoregressive model + path YT0→ ∆X (β + γ2)
• Reciprocal model: expected + reverse model (β + γ1 and γ2)
The models were compared using Chi2. First, we compared the expected, reverse and reciprocal
models to the autoregressive model to retain those which fit the data significantly better than the
autoregressive model. We then discarded the retained reciprocal model if it did not fit the data better
than the retained unidirectional model. If the reciprocal model was retained, we specified a constrained
reciprocal model by fixing the unstandardized γ1 and γ2 coefficients to equality to test whether both
paths were significantly different (i.e., whether a variable had a causal predominance). The direction of
the “expected” path was based on theoretical assumptions. Because antipsychotics affect insight [42],
QoL [43,44], depression [45], and suicide [46], chlorpromazine equivalent doses were added as a
covariate. Negative, positive and general schizophrenic symptomatology were added as covariates to
control for their potential confounding effect in the relationships between insight, QoL, depression,
and suicide [12,47,48].
Finally, we estimated a multivariate model that included all the variables and simultaneously
tested all the relationships contained in the retained bivariate models.
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3. Results
3.1. Participants and Evolution of the Measures
We included 738 patients between March 2010 and June 2017. A total of 370 patients participated
in both evaluations, whereas 368 (49.9%) dropped out after the first evaluation. There was no significant
difference between completers and non-completers, reflecting minimal attrition bias (Table S2). Only the
BIS score (Student’s t test: p= 0.052, d= 0.15; Wilcoxon’s signed rank test: p= 0.087) and chlorpromazine
equivalent doses (Student’s t test: p = 0.055, d = 0.15; Wilcoxon’s signed ranks test: p = 0.006) were
marginally higher in the non-completers than completers, with very small effect size (<0.2).
The final sample included 344 patients after excluding those > 30% missing data. Characteristics
of the sample and evolution of the variables are described in Table 1.
Table 1. Socio-demographic and clinical characteristics of the final sample and evolution of the
variable of interest between inclusion and follow-up (BIS: Birchwood Insight Scale; SUMD: Scale
to assess Unawareness of Mental Disorder; PANSS: Positive And Negative Syndrome Scale; S-QoL:
Schizophrenia Quality of Life; CDS: Calgary Depression Scale; Scz-aff: schizo-affective; Scz-form:
schizophreniform; n: count).
Baseline Follow-up p d Statistics
Mean SD Mean SD
Age (years) 32.4 9.4
Age at onset (years) 21.6 6.4
Total duration of hospitalization (months) 7.6 10
Insight latent score 0 1.75 0.46 1.65 <0.001 0.27 t(343) = −5.35
BIS (0–12) 8.87 2.81 9.19 2.65 0.066 0.117 t(290) = −1.84
SUMD (0–100) 30.46 32.03 22.91 29.98 0 −0.242 t(298) = 4.84
PANSS G12 (1–7) 3.13 1.52 2.82 1.55 0 −0.201 t(329) = 3.92
Quality of life latent score 0 21.27 7.95 20.94 <0.001 0.37 t(307) = −7.85
Self-Esteem (0–100) 46.76 30.21 56.88 26.31 0 0.352 t(307) = −6.96
Resilience (0–100) 55.17 25.91 59.53 25.6 0.005 0.169 t(307) = −2.85
Autonomy (0–100) 58.73 27.81 61.64 26.02 0.029 0.108 t(307) = −2.2
Physical well-being (0–100) 45.29 27.84 51.33 26.06 0 0.223 t(307) = −4.14
Psychological well-being (0–100) 51.41 27.31 58.72 26.4 0 0.27 t(307) = −4.43
Family relationships (0–100) 69.16 25.51 71.99 23.57 0.034 0.115 t(307) = −2.13
Friends relationships (0–100) 47.18 28.64 54.45 26.31 0 0.262 t(307) = −4.27
Sentimental life (0–100) 33.85 28.75 37.77 28.66 0.018 0.136 t(307) = −2.37
CDS without suicide item (0–24) 3.91 4.02 2.76 3.22 0 −0.312 t(327) = 6.12
Calgary suicide item 0.27 0.61 0.2 0.48 0.032 −0.127 t(328) = 2.15
Risk of suicide (0–5) 1.4 1.78 0.98 1.46 0 −0.297 t(313) = 5.07
PANSS Positive (7–49) 14.87 5.28 13.09 4.7 0 −0.351 t(329) = 6.54
Negative (7–49) 20.99 7.17 18.7 7.18 0 −0.315 t(329) = 6.57
General without G12 (16–105) 35.63 9.66 32.69 9.22 0 −0.308 t(329) = 5.96
Chlorpromazine equivalent doses 517.39 590.67 585.33 682.51 0.042 0.106 t(262) = −2.04
n % n %
Sex, male 264 76.7
Schizophrenia/Scz-aff/Scz-form disorder 269/72/3 78.2/20.9/0.9
Hospitalized the current year 132 38.9
Suicide attempt over the past year, yes 26 7.6 6 1.7
We found significant changes over time in all the variables of interest with very small to small effect
sizes (Table 1). Using Wilcoxon’s signed ranks test to account for non-normality in the distributions
of chlorpromazine equivalent doses, the evolution of this variable over time was not significant
(p = 0.086).
A description of diagnosis subgroups (schizophrenia and schizo-affective disorder) can be found
in Supplementary Table S1.
3.2. Model Comparisons
3.2.1. Bivariate Models
Table 2 presents the path coefficients for the retained bivariate models. Model comparisons are
presented in Table S3. In sum, we found that in terms of:
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• Insight and quality of life, the best-fitting model was the expected model, suggesting that insight
causes change in QoL.
• Quality of life and depression, the best-fitting model was the expected model, suggesting that
QoL causes change in depression.
• Depression and suicidality, the best-fitting model was the reciprocal model. We estimated
whether the two paths were significantly different by testing a constrained model, with coupling
path coefficients fixed to equality. The constrained model did not fit the data significantly worse
than the unconstrained model. Thus, we cannot conclude whether one link was significantly
different than the other.
• Insight and depression, the best fitting model was the expected model, suggesting that insight
causes change in depression.
• Insight and suicidality, the best fitting model was the expected model, suggesting that insight
causes change in suicidality.
• Quality of life and suicidality, the best fitting model was the autoregressive model (no coupling
path), suggesting that QoL and suicidality do not directly affect each other.
Table 2. Unstandardized (B) and standardized (β) coupling and autoregressive path (→) and covariance
(←→) coefficients and statistics in the retained bivariate models (QoL: quality of life, Dep: depression,
Sui: suicidality, Ins: insight, ∆X: change in variable X; CFI: comparative fit index; TLI: Tucker–Lewis
index; RMSEA: root mean square error of approximation; SRMR: standardized root mean square
residual).
Path B (β) SE Z p
QoL and depression
CFI = 0.951,
TLI = 0.947,
RMSEA < 0.05 (p = 1),
SRMR = 0.05
QoL→ ∆QoL −0.39 (−0.47) 0.06 −6.99 <0.001
Dep→ ∆Dep −0.71 (−0.71) 0.06 −11.73 <0.001
QoL→ ∆Dep −0.21 (−0.17) 0.08 −2.51 0.01
QoL←→ Dep −0.28 (−0.46) 0.05 −6.22 <0.001
∆QoL←→ ∆Dep −0.2 (−0.45) 0.04 −5.5 <0.001
QoL and suicidality
CFI = 0.952,
TLI = 0.949,
RMSEA < 0.05 (p = 1),
SRMR = 0.049
QoL→ ∆QoL −0.41 (−0.49) 0.06 −7.1 <0.001
Sui→ ∆Sui −0.63 (−0.58) 0.06 −11.11 <0.001
QoL←→ Sui −0.16 (−0.23) 0.05 −3.5 <0.001
∆QoL←→ ∆Sui −0.14 (−0.26) 0.04 −3.58 <0.001
Depression and suicidality
CFI = 0.959,
TLI = 0.912,
RMSEA < 0.05 (p = 0.23),
SRMR = 0.034
Dep→ ∆Dep −0.66 (−0.66) 0.06 −11.86 <0.001
Sui→ ∆Sui −0.71 (−0.66) 0.06 −11.74 <0.001
Dep→ ∆Sui 0.22 (0.2) 0.05 4.15 <0.001
Sui→ ∆Dep 0.1 (0.1) 0.05 2.08 0.038
Dep←→ Sui 0.29 (0.36) 0.05 5.61 <0.001
∆Dep←→ ∆Sui 0.2 (0.29) 0.04 4.64 <0.001
Insight and depression
CFI = 0.933,
TLI = 0.91,
RMSEA = 0.065,
SRMR = 0.047
Ins→ ∆Ins −0.39 (−0.52) 0.09 −4.4 <0.001
Dep→ ∆Dep −0.64 (−0.64) 0.05 −12.1 <0.001
Ins→ ∆Dep 0.25 (0.16) 0.08 3.13 0.002
Ins←→ Dep 0.07 (0.14) 0.03 2.03 0.042
∆Ins←→ ∆Dep 0 (0.01) 0.02 0.15 0.88
Insight and QoL
CFI = 0.928,
TLI = 0.923,
RMSEA < 0.05 (p = 0.97),
SRMR = 0.056
Ins→ ∆Ins −0.4 (−0.54) 0.05 −7.4 <0.001
QoL→ ∆QoL −0.42 (−0.5) 0.06 −7.61 <0.001
Ins→ ∆QoL −0.14 (−0.14) 0.07 −2.08 0.038
Ins←→ QoL −0.1 (−0.24) 0.03 −3.39 0.001
∆Ins←→ ∆QoL −0.02 (−0.11) 0.02 −1.23 0.22
Insight and suicidality
CFI = 0.95,
TLI = 0.932,
RMSEA < 0.05 (p = 0.32),
SRMR = 0.045
Ins→ ∆Ins −0.31 (−0.48) 0.09 −3.36 0.001
Sui→ ∆Sui −0.66 (−0.61) 0.06 −11.21 <0.001
Ins→ ∆Sui 0.24 (0.15) 0.08 3.12 0.002
Ins←→ Sui 0.01 (0.17) 0.03 2.89 0.004
∆Ins←→ ∆Sui 0.05 (0.15) 0.03 1.98 0.048
3.2.2. Final Multivariate Model
The global model had good fit indices: CFI = 0.942, TLI = 0.935, RMSEA < 0.05 (p = 1),
SRMR = 0.055. The relationships found in the bivariate models remained significant when considering
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all the variables together, except the path from suicidality to change in depression (Figure 1 and
Table S4). The model shows that insight predicts changes in QoL, depression, and suicidality. Moreover,
QoL predicts changes in depression, and depression predicts changes in suicidality but not the reverse.
The model accounted for 38.5% of the variance in the latent change of suicidality.
A simplified diagram of the global model is presented in Figure 2, presenting the estimated paths
of interest. Variables at T12 are not depicted, as the paths coefficients from and to them were fixed at
1 (XT0→ XT12, ∆X→ XT12). The zero-order correlation matrix for the variables of interest is provided
in Supplementary Table S5.
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The parameters of the model remained comparable after the exclusion of the three patients with
schizophreniform disorders.
4. Discussion
The main strength of this study is that it is the first to examine the structure of the longitudinal
relationships between insight, QoL, depression and suicidality in individuals with a schizophrenia
spectrum disorder. The present study benefited from a large sample of patients with stabilized
schizophrenia spectrum disorders (n = 344) and was based on statistical methods that allow the study of
the dynamics of change between several variables. As recommended, we used both self-reported and
clinician-rated measures of insight, and we took care to control for the potential effects of antipsychotics
and negative, positive, and general schizophrenic symptomatology.
The data strongly support a unidirectional relationship between insight and suicidality, with good
insight predicting a worsening of suicidality. Our model also reflects that good insight predicts
a decrease in QoL and that low QoL predicts a worsening of depression. The results were more
ambiguous concerning the relationship between depression and suicidality, as the bivariate model
including reciprocal relationships explained the data better than the model with only a unidirectional
relationship from depression to change in suicidality. However, in the multivariate model, the path
from suicidality to change in depression was not significant anymore, whereas the path from depression
to change in suicidality remained significant. This result could be explained by the fact that suicide
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and depression may be more closely intertwined than the other clinical dimensions included in the
model, and it might not be possible to disentangle them properly in schizophrenia.
All these relationships survived the addition of positive and negative symptoms, general
psychopathology, and chlorpromazine equivalent doses as covariates and the multivariate model
explained 38.5% of the variance in change in suicidality. The bivariate relationship between insight and
suicidality survived in the multivariate model, suggesting a direct effect of insight on suicidality and
the absence of total mediation through depression and QoL. This result appears to contradict those of
previous studies that showed a complete mediation of the relationship between insight and suicidality
through depression and QoL [16,18,19]. This longitudinal model suggests a temporal sequence, such as
a better insight precedes a decrease in QoL, and poor QoL leads to increased depression. This temporal
sequence is compatible with the defense theory of insight [7], which postulates that depression occurs
after an improvement of insight because of a more accurate view of the negative impact of the disorder
on QoL. This association may be mediated by high internalized stigma, hopelessness, low self-esteem,
or rumination [12]. The absence of direct relationships between QoL and suicidality in both the bivariate
and multivariate models contradicts the results of previous studies [17,49]. The escape theory of suicide
predicts that when QoL decreases, the discrepancy between patients’ current appraisal of their situation
and their expectations prompts suicide. According to this theory, the relationship between QoL and
suicidality is direct, but also indirect “via negative affect, especially depression and anxiety” [50].
The results of the present study suggest that the impact of QoL on suicidality is exclusively indirect:
poor QoL cannot explain an increase in suicidality in the absence of depression. Moreover, our results
support the assumption that better insight is associated with negative consequences in terms of QoL,
depression, and suicidality. Since better insight yields better clinical outcomes but also has adverse
effects, we advocate that insight-targeted interventions, such as psychoeducation, should only be
carried out with particular attention paid to depressive symptoms and subjective QoL at each step of
the process.
We also found globally small but significant improvements in insight, QoL, depression,
and suicidality during the 12-months follow-up period. Although difficult to interpret, this trend
could be partially explained by the follow-up in the centers of expertise which provide patients with
personalized recommendations concerning disease management and treatment.
Despite its strengths, this study has several limitations. First, our sample consisted of clinically
stabilized patients who were not randomly selected. Thus, the results may not be generalizable to the
general population of individuals with schizophrenia spectrum disorders. However, the characteristics
of the sample were in accordance with previous studies in terms of insight [24] and QoL [29], thus
improving the generalizability of the results to the population with stabilized schizophrenia spectrum
disorders. Nearly 50% of the included patients were lost to follow-up. No survey was proposed
to the non-completers, making it impossible to investigate the reasons for dropping out. However,
comparisons between completers and non-completers did not show any significant differences,
suggesting minimal attrition bias. We used a non-validated tool to evaluate suicidality, and both
suicidal ideation and behaviors were parts of the scale, whereas different mechanisms and risk factors
might play a role [17,51]. We did not control for the presence of substance use disorders, which may
have a crucial influence on QoL and suicidality [52,53], and we did not distinguish between patients
with schizophrenia, schizoaffective disorder, schizophreniform disorder or patients with first-episode
psychosis. A complete causal model cannot be inferred from our data, as we did not actively manipulate
insight, QoL, depression, or suicidality in a randomized controlled trial. Our two-timepoints design
does not allow distinguishing the change between a constant change (overall rate of change across
all time points) and a proportional change (depending on the adjacent measurement occasions), nor
investigation of the effects of change in one variable on subsequent changes in others. Our results
should, thus, be replicated by alternative longitudinal SEM, such as dual change score models or an
autoregressive latent trajectory with structured residuals, which require, however, at least four and
three timepoints, respectively.
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5. Conclusions
According to our model, higher insight detrimentally affects QoL, depression, and suicidality,
and these effects add up to those which could be interpreted as a temporal cascade from QoL to
suicidality via depression. This model calls for the monitoring of adverse effects of insight-targeted
interventions by combining them with preventive strategies for depression. Finally, those interventions
should not be proposed to patients with major depression.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/8/1196/s1,
Figure S1: Model adapted from Roux et al. (2018), Supplementary methods, Table S1: Characteristics of
diagnosis subgroups at inclusion; Table S2: Comparison between completers and non-completers, Table S3: Model
comparisons, Table S4: Unstandardized and standardized coupling and autoregressive path coefficients and
statistics in the final multivariate model, Table S5: Zero-order correlation matrix for the variables of interest.
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